Descripción de la empresa
Ainos, Inc. operates as a dual-platform enterprise within the technology sector, specifically focusing on scientific and technical instruments through its innovative integration of SmellTech, AI diagnostics, and immune therapeutics. The company's core business involves the development of an AI Nose platform that utilizes a smell language model to digitize scent data into Smell IDs, effectively converting invisible chemical signals into machine-readable information for diagnostic applications. Currently, the firm maintains a market capitalization of $10.75M and reports trailing twelve-month revenue of $124,157, while its employee count is not disclosed in available public records. These financial dimensions indicate a micro-cap status with significant revenue concentration relative to its valuation, suggesting the company is in an early-stage development phase where capital efficiency and high-margin product adoption are critical drivers of future positioning rather than established market dominance.
Salud financiera
The financial statements for the trailing twelve months show a revenue of $124,157 against a net income of $-14,771,012 and an EBITDA of $-9,210,258, revealing a severe disconnect between top-line sales and bottom-line profitability that points to substantial ongoing operational losses or significant one-time charges. Despite the negative net income, the company generated a positive free cash flow of $52,412, which provides a limited but crucial buffer for financial flexibility and operational continuity in the absence of external financing. The margin profile displays a gross margin of 82.9%, indicating high production efficiency, yet this is overshadowed by an operating margin of -38648.0% and a profit margin of 0.0%, signaling that overhead costs or restructuring expenses are disproportionately large relative to current sales. On the balance sheet, the company holds $417,353 in cash against $11.00M in debt, resulting in a debt-to-equity ratio of 145.45% that characterizes a highly leveraged position rather than a conservative capital structure. Liquidity is further assessed by a current ratio of 1.06, which suggests the firm can technically meet its short-term obligations but operates with minimal cushion against working capital shocks. Return metrics reflect this financial pressure, with a return on equity of -128.0% and a return on assets of -35.2%, demonstrating that management has not yet generated positive returns on the capital base deployed to build the platform.
Evaluación de valoración
Valuation multiples for Ainos, Inc. present a complex picture due to the lack of traditional profitability metrics, as the trailing P/E ratio is N/A and the forward P/E is also N/A, implying that current earnings are negative and future earnings expectations are either not yet materialized or are too speculative for standard multiple modeling. The price-to-book ratio stands at 1.15, which suggests the market values the company at a slight premium over its tangible book value, potentially reflecting optimism regarding the intangible assets inherent in its AI and biotech technologies. Alternative valuation metrics such as a price-to-sales ratio of 86.61 and an EV/EBITDA of -2.32 indicate that investors are pricing the stock primarily on revenue potential rather than current earnings power, a common characteristic for early-stage technology firms. The stock has traded within a range defined by a 52-week high of $4.50 and a 52-week low of $1.26, placing the current share price somewhere within this volatile band where valuation compression or expansion is highly sensitive to market sentiment. The beta of 2.32 reveals that the stock exhibits price volatility significantly higher than the broader market, meaning that Ainos, Inc. tends to amplify market movements and presents elevated risk for price swings relative to large-cap equities.
Growth & Income
Regarding growth dynamics, the available data lists revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, preventing a direct comparison of earnings versus revenue expansion rates at this specific point in time. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, confirming that all generated earnings are being retained to fund research, development, and debt reduction rather than being distributed to shareholders. This reinvestment strategy is typical for technology companies in the scientific and technical instruments industry that prioritize scaling their AI Nose platform and immune therapeutics pipeline over immediate shareholder returns. The overall growth and income profile for Ainos, Inc. is currently defined by a reliance on capital appreciation driven by future product adoption rather than a history of consistent earnings growth or dividend income streams.